Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
Should an Emerging Biotech Commercialize Independently or Partner?
Neither strategy is universally correct. The decision should begin with a realistic understanding of what commercialization actually requires.
Read ArticleA Commercial Readiness Checklist for a Biotech Company's First Product Launch
A first product launch is a company transformation. Leadership should evaluate readiness across market understanding, access, organization, governance and execution.
Read ArticleWhen Should an Emerging Biotechnology Company Start Commercial Planning?
Commercialization is not an event that begins when a commercial organization is hired. It is the culmination of decisions made throughout development.
Read ArticleCAH Commercialization
Why commercial success for atumelnant will depend on diagnosis, market strategy, and commercial discipline—not pharmacology alone.
Read ArticleThe Eight Principles of Product Commercialization
A successful product launch begins long before FDA approval—commercialization is a series of strategic decisions that determine whether an innovative therapy reaches patients.
Read ArticleWhen Companies Buy More Than a Product
Lessons from the Immedica–Marinus acquisition on building a rare disease commercial platform—why infrastructure and capabilities can matter more than current product revenue.
Read ArticlePediatric Developmental & Epileptic Encephalopathies (DEE)
Commercial strategy for ultra-rare pediatric neurology—why success now depends on developmental outcomes, quality of life, and caregiver burden, not seizure reduction alone.
Read ArticleWhy Leadership Decisions Determine Commercial Success
Commercial success is rarely determined by the quality of the science alone—it is designed by leaders who make disciplined decisions long before launch.
Read Article